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The aim of this study was to determine the long-term outcomes (all-cause mortality and 
sudden cardiac death [SCD]) after medical therapy, alcohol septal ablation (ASA), and 
myectomy in patients with hypertrophic cardio- myopathy (HCM). 
BACKGROUND Therapy-resistant obstructive HCM can be treated both surgically and 
percutaneously. But there is no consensus on the long-term effects of ASA, especially on 
SCD. 
Methods  
This study included 1,047 consecutive patients with HCM (mean age 52 ± 16 years, 61% 
men) from 3 tertiary referral centers. A total of 690 patients (66%) had left ventricular 
outflow tract gradients < 30 mmHg, of whom 124 (12%) were treated medically, 316 (30%) 
underwent ASA, and 250 (24%) underwent myectomy. Primary endpoints were all-cause 
mortality and SCD. Kaplan-Meier graphs and Cox regression models were used for statistical 
analyses. 
Results  
The mean follow-up period was 7.6 ± 5.3 years. Ten-year survival was similar in medically 
treated patients (84%), ASA patients (82%), myectomy patients (85%), and patients with 
nonobstructive HCM (85%) (log-rank p = 0.50). The annual rate of SCD was low after 
invasive therapy: 1.0%/year in the ASA group and 0.8%/year in the myectomy group. 
Multivariate analysis demonstrated that the risk for SCD was lower after myectomy compared 
with the ASA group (hazard ratio: 2.1; 95% confidence interval: 1.0 to 4.4; p 1⁄4 0.04) and the 
medical group (hazard ratio: 2.3; 95% confidence interval: 1.0 to 5.2; p = 0.04). 
Conclusions  
Patients with obstructive HCM who are treated at referral centers for HCM care have good 
survival and low SCD risk, similar to that of patients with nonobstructive HCM. The SCD 
risk of patients after myectomy was lower than after ASA or in the medical group.  
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Hypertrophic cardiomyopathy (HCM) is the most prevalent inheritable myocardial dis- ease, 
and (provocable) left ventricular 
outflow tract (LVOT) obstruction is present in the majority of patients with HCM (±70%) (1). 
Not only is LVOT obstruction associated with symptoms such as dyspnea on exertion, 
fatigue, chest pain, and syncope, but previous studies have also demonstrated that the 
presence of obstruction increases all-cause mortality and the occurrence of sudden cardiac 
death (SCD) in these patients (2,3), and it is included as a risk factor in the novel clinical risk 
prediction model presented by the HCM Outcomes Investigators (4). 
Therapy-resistant obstructive HCM can be treated both surgically and percutaneously, and in 
recent years there has been an intense and polarizing debate to define the best strategy (5–8). 
Surgical approaches have been used for more than 5 decades, and at experienced centers, 
relief of obstruction can be achieved with minimal perioperative morbidity and mortality (9–
11). However, myectomy is open-heart surgery with relatively long rehabilitation, so in 1995, 
alcohol septal ablation (ASA), a percutaneous alternative, was developed (12). This strategy 
was quickly adopted all over the world, and patients who underwent ASA quickly 
outnumbered those who underwent myectomy (5–8,12,13). In some European countries, ASA 
has fully replaced myectomy (7). Concerns about ASA remain, however, especially about the 
arrhythmogenic effect of the ablation scar in patients already at increased risk for life- 
threatening arrhythmias (14–17). 
Although a randomized controlled trial does not seem feasible (18), and recent meta-analyses 
(19,20) evaluated only short-term SCD rate and survival, there is no consensus on the long-
term outcomes of ASA (17,21–24). The aim of the present study was therefore to determine 





Study design and population. 
 An international multicenter, observational cohort design was used. The study conformed to 
the principles of the Declaration of Helsinki. All patients gave informed consent for the 
intervention, and local institutional review board approval was obtained. 
The study population consisted of 1,065 consecutive patients with HCM from University 
Hospital Leuven (Leuven, Belgium; n = 200), St. Antonius Hospital Nieuwegein 
(Nieuwegein, the Netherlands; n = 318), and Thoraxcenter, Erasmus Medical Center 
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(Rotterdam, the Netherlands; n = 547). Each patient had an established diagnosis of HCM, 
based on unexplained left ventricular hypertrophy of ≥15 mm, assessed by echocardiography 
(25,26). Patients with HCM linked to Noonan’s syndrome, Fabry’s disease, mitochondrial 
disease, or congenital heart defects were excluded. 
The LVOT gradient was measured in all patients using continuous-wave Doppler 
echocardiography, at rest and after provocative maneuvers. Patients were considered to have 
obstructive HCM if the LVOT gradient was ≥ 30 mm Hg, at rest or after provocation. 
Invasive therapy was indicated if the peak LVOT gradient was ≥ 50 mm Hg, ventricular 
septal thickness was ≥ 15 mm, and there was persistent New York Heart Association (NYHA) 
functional class III or IV dyspnea or Canadian Cardio- vascular Society class III or IV angina 
despite optimal medical therapy (26). Patients without LVOT gradients ≥ 30 mmHg after 
provocation were considered to have nonobstructive HCM and used as a control group. 
Patients with obstructive HCM were classified in 3 groups on the basis of the clinical 
treatment strategy: a medically treated group, an ASA group, and a myectomy group. Surgical 
septal myectomy was performed throughout the study period and as described previously 
(27,28), and postoperative care was in accordance with local protocols. ASA was performed 
starting from 1999 as described previously (28,29). Afterward, all patients were monitored for 
at least 24 h in the intensive coronary care unit. 
 
Endpoints 
The primary endpoints of this study were all-cause mortality and SCD-related events. The 
SCD endpoint was a composite endpoint consisting of: 1) instantaneous and unexpected death 
within 1 h of witnessed collapse in patients who were previously in stable clinical condition, 
or nocturnal death with no antecedent history of worsening symptoms; 2) successful 
resuscitation after cardiac arrest; 3) appropriate implantable cardioverter-defibrillator (ICD) 
intervention for ventricular fibrillation or for fast ventricular tachycardia (>200 beats/min); 
and 4) unknown cause of death. Unknown death was included in the SCD endpoint to 
estimate the maximal occurrence of SCD in the population. We also evaluated periprocedural 
arrhythmic events and mortality, reinterventions, LVOT gradient reduction, and implantation 
of ICDs. 
Mortality and adverse events were retrieved from hospital patient records at the center at 
which follow- up occurred, from civil service population registers, and from information 
provided by patients them- selves or their general practitioners. Cardiac trans- plantation was 
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considered an HCM-related death, and patients were censored at the time of transplantation. 
All ICD interventions were evaluated by an experienced electrophysiologist. 
 
 
Data collection and follow-up.  
Follow-up started at the time of intervention. In the medically treated cohort, follow-up 
started at the first outpatient clinic contact after January 1, 1990. At baseline, all patients were 
evaluated for the following characteristics: NYHA class, maximal left ventricular wall 
thickness, maximal (provocable) LVOT gradient, systolic and diastolic left ventricular 
function, and medications used. During follow-up, the established risk factors for SCD were 
evaluated (25,26). Other potential modifiers of SCD risk were also examined: atrial 
fibrillation and coronary artery disease. In patients treated with ASA, the dose of alcohol used 
was also collected. 
If no endpoints occurred during follow-up, the final censoring date was set at November 1, 
2012. If alternative septal reduction therapy was necessary (e.g., ASA after myectomy or vice 
versa), follow-up was censored at the date of the second intervention, because of the difficulty 




SPSS version 20 (IBM, Armonk, New York) and Excel 2010 (Microsoft Corporation, 
Redmond, Washington) were used for all statistical analyses. Categorical variables are 
summarized as percentages. Normality was assessed using the Shapiro-Wilk test combined 
with visual inspection of histograms and Q-Q plots. Normally distributed continuous data are 
expressed as mean ± SD and non- normally distributed data as median (interquartile range 
[IQR]). To compare continuous variables, Student t tests, Mann-Whitney U tests, and one-
way analysis of variance were used. When appropriate, post hoc comparisons were carried out 
using Bonferroni correction. To compare categorical variables, chi-square tests were used. To 
identify clinical predictors of SCD mortality, univariate and multivariate Cox regression 
analyses were used. Variables were selected for multivariate analysis if univariate p values 
were <0.10 and are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). 
The final number of variables was restricted according to the number of endpoint events to 
avoid overfitting the multivariate model. All tests were 2 sided, and p values <0.05 were 





Table 1 lists the baseline characteristics of all patients. Of the 1,065 patients (mean age 52 ± 
16 years, 61% men) included in this study, 716 (67%) had obstructive HCM; in 269 (25%), 
LVOT obstruction was present only after provocation. Of these 716 patients, 142 (20%) were 
treated medically, 321 (45%) underwent ASA, and 253 (35%) underwent myectomy. Patients 
in the ASA group were older (58 ± 14 years) than those in the surgery group (52 ± 16 years, p 
< 0.001) and in the medical group (53 ± 15 years, p = 0.001). The majority of medically 
treated patients (n = 124 [87%]) reported no symptoms or mild (NYHA functional class I or 
II) symptoms at baseline, despite a mean LVOT gradient of 70 ± 32 mm Hg. The other 18 
patients (13%) had indications for invasive treatment but were considered not eligible because 
of severe comorbidities (e.g., 1 patient had liver cirrhosis due to alcohol abuse and kidney 
failure) or patient refusal (several patients refused further invasive treatment, mostly because 
they were at old age and preferred no further interventions). In this group, mortality was high 
(8 deaths [44%]), and these patients were excluded from further analysis. 
The distribution of established risk factors for SCD, among the 3 intervention groups and 
controls, is shown in Table 1. Complete risk stratification was not available for all patients: 
blood pressure response during exercise testing was available in 645 patients (61%), and 
documented rhythm information was available in 656 patients (62%). Significantly more 
patients in the myectomy group (n = 44 [17%]) had ≥ 2 established risk factors for SCD than 
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Values are mean ± SD or n (%). 
ASA = alcohol septal ablation; BP = blood pressure; EF = ejection fraction; HCM = 
hypertrophic cardiomyopathy; LVOT = left ventricular outflow tract; LVWT = left 
ventricular wall thickness; NYHA = New York Heart Association; SCD = sudden cardiac 
death; VT = ventricular tachycardia. ∗p < 0.05, †p < 0.01, and ‡p < 0.001 compared with controls. 
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Procedural data.  
Invasive therapy was performed in 574 patients with obstructive HCM. Periprocedural 
mortality was similar between ASA (n 1⁄4 5 [1.6%]) and myectomy (n 1⁄4 3 [1.2%]) (p 1⁄4 
0.70). In the first 30 days post-procedure, ventricular ar- rhythmias occurred more frequently 
in the ASA group (n 1⁄4 11 [3.1%]) than in the myectomy group (n 1⁄4 1 [0.4%]) (p < 0.001). 
Cardiac resuscitation was neces- sary in 7 ASA patients (2.2%). Residual LVOT gradient was 
measured after 3 months and was reduced after both ASA and myectomy: from a median of 
97 mm Hg (IQR: 66 to 130 mm Hg) to 10 mm Hg (IQR: 1 to 24 mm Hg) after ASA, and from 
a median of 90 mm Hg (IQR: 70 to 100 mm Hg) to 9 mm Hg (IQR: 0 to 16 mm Hg) after 
myectomy. In 31 ASA patients (9.7%), additional septal reduction therapy was necessary, and 
this was higher than after myectomy (n 1⁄4 6 [2.3%], p < 0.001) (Table 2). 
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Table 2 Invasive Therapy in 574 patients with HCM 
Variable0 ASA00 Myectomy00
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Values are n (%) or mean ± SD. 
NA = not applicable; other abbreviations as in Table 1. ∗In 53 patients (16.5%), the dose of alcohol could not be retrieved. 
†p < 0.01. 




In 1,047 patients, mean follow-up duration was 7.5 ± 5.3 years (maximum 22.8 years). There 
were 156 deaths in the entire cohort (Table 3): 8 (5%) were procedure related, 80 (51%) were 
HCM related, 56 (36%) patients died of noncardiac causes, and causes of death were 
unknown in 12 (8%). Twelve patients underwent cardiac transplantation and were considered 
as HCM-related death. Kaplan-Meier estimates of survival are shown in Figure 1A. Five-year 
and 10-year survival was similar after ASA, myectomy, and medical treatment in patients in 
NYHA class I or II and those with nonobstructive HCM (Table 3). Independent predictors of 
all-cause mortality were age (HR: 1.05; 95% CI: 1.0 to 1.1; p < 0.001); systolic dysfunction, 
with ejection fraction <50% (HR: 1.8; 95% CI: 1.2 to 2.6; p = 0.005); and a trend toward 
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Values are mean ± SD or n (%). 
CA = cardiac arrest; ICD = implantable cardioverter-defibrillator; other abbreviations as in 
Table 1. ∗p < 0.05. 
†p < 0.001 compared with controls. 




Table 4 Analysis of Clinical Variables Associated with SCD and All-cause Mortality in 1047 
Patients With HCM!! """""""Univariate! """"""""Multivariate!Variable! HR! CI!95%! p"Value" HR! CI!95%! p"Value"
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Backward multivariate Cox regression analysis was used. 
CI = confidence interval; HR = hazard ratio; other abbreviations as in Table 1. 
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Figure 1 Survival in 1047 patients with HCM 
 
 Kaplan-Meier graphs of survival (A) and survival free of sudden cardiac death (B) in 1,047 




The SCD endpoint occurred in 76 patients over 8,003 patient-years (0.9%/year). The annual 
SCD rate was 0.96%/year after ASA, 0.76%/year after myectomy, 1.26%/year in medically 
treated groups, and 1.02%/year in nonobstructive HCM patients (p = 0.40). Appropriate ICD 
shocks were more common after ASA (in 8 of 41 patients [20%]) than after myectomy (in 1 
of 29 patients [3.4%]) (p = 0.03). Other characteristics of SCD are described in Table 3. 
Kaplan-Meier estimates of survival free from SCD are shown in Figure 1B. Multivariate 
analysis identified the following independent predictors of SCD: patients who survived 
ventricular fibrillation or sustained ventricular tachycardia (HR: 6.0; 95% CI: 3.4 to 10.6; p < 
0.001), patients with >2 established risk factors (HR: 2.7; 95% CI: 1.6 to 4.4; p < 0.001), 
patients with atrial fibrillation (HR: 1.7; 95% CI: 1.1 to 2.8; p 1⁄4 0.03), and, when compared 
with myectomy, ASA (HR: 2.1; 95% CI: 1.0 to 4.4; p = 0.04) and medically treatment (HR: 
2.3; 95% CI: 1.1 to 5.1; p 1⁄4 0.04) (Table 4). 
 
Discussion 
The purpose of this investigation was to compare the long-term effects of medical treatment, 
ASA, and myectomy on all-cause mortality and SCD in patients with obstructive HCM. There 
were 2 important results. First, the mortality rates in patients with prior ASA or myectomy 
and in medically treated patients in NYHA functional class I or II were similar to those in 
patients with nonobstructive HCM. Second, the long- term risk for SCD was low after both 
myectomy (0.8%/year) and ASA (1.0%/year), a small but signifi- cant difference (HR for 
SCD after ASA vs. myectomy: 2.1; p = 0.04). 
 
Low Mortality in patients with obstructive HCM 
The observed survival after both myectomy (10-year survival 85%) and ASA (10-year 
survival 82%) (p = 0.50) was similar to that in patients with nonobstructive HCM (85%) (p = 
0.70 and p = 0.20, respectively). This demonstrates that the survival disadvantage associated 
with LVOT obstruction can be effectively annulled by appropriate invasive therapy and 
management at referral centers for HCM care (2). ASA was performed in carefully selected 
patients who were older and had more comorbidities (61% of the deaths were due to 
noncardiac causes), but despite this, the observed mortality after ASA was not significantly 
higher than in the other groups. The observed survival after invasive therapy in this study 
confirms other studies evaluating long-term outcomes for the individual approaches (21-24) 
The good survival of patients with obstructive HCM who remained in NYHA class I or II on 
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optimal medical therapy (10-year survival 84%) could imply that earlier intervention in 
asymptomatic or mildly symptomatic patients with obstructive HCM is not indicated, despite 
the low procedural mortality and morbidity of both invasive therapies. Mortality, not 
surprisingly, was high (44%) in a limited group of patients (n = 18 [13%]) with indications for 
invasive treatment (NYHA class III or IV despite optimal medical therapy) but who were 
deemed to be ineligible because of severe comorbidities. 
 
 
SCD After ASA 
Since the introduction of ASA, there have been concerns regarding the arrhythmogenic effect 
of the ablation scar in patients already at increased risk for life-threatening arrhythmias. 
Studies of short-term follow-up after ASA have described frequent episodes of sustained 
ventricular tachycardia and ventricular fibrillation (14, 15, 16 and 17). Our findings confirm 
this and show that although arrhythmic events were more frequent after ASA (3.1%) than 
after myectomy (0.4%) (p < 0.001), this had no effect on procedure-related mortality (1.6% 
vs. 1.2%, p = 0.70). The aim of this study was to assess the long-term effects of the different 
treatment modalities, especially because the long-term effect of ASA on SCD is unclear. 
Two meta-analyses showed that the risk for SCD was not higher in ASA patients than in 
patients who underwent myectomy. These studies did not focus on long-term outcomes: the 
mean follow-up period across the cohorts in a study by Agarwal et al. (19) was <3 years, and 
in a study by Leonardi et al. (20), there was a significant difference in follow-up duration 
between the ASA and myectomy cohorts, with median follow-up durations of 1,266 patient-
years in the myectomy studies and 51 patient-years in the ASA studies. Other concerns, 
especially about the calculated SCD risk, have already been illustrated by Nishimura and 
Ommen (30). The risk for SCD after myectomy has generally been low (11), and the study by 
McLeod et al. (31) even suggests that myectomy could decrease the risk for SCD. 
Our study found that the annual SCD rate (excluding periprocedural events) in patients who 
underwent ASA was 1.0%/year, which was similar to that in patients with nonobstructive 
HCM and medically treated patients. A study by ten Cate et al. (17), which included a subset 
of the patients from the present study, reported a higher SCD rate than this study. The reason 
for this is 2-fold: 1) a separate endpoint for SCD (instead of a composite of cardiac mortality 
and SCD) was used, and 2) we excluded periprocedural events from the final analysis to focus 
on the long-term effects of ASA. Two recently published studies with long-term follow-up 
found that the risk for SCD was not high after ASA. Jensen et al. (23) examined 470 ASA 
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patients, with a mean follow- up period of 8.4 years, and found an annual SCD rate of 
0.5%/year. Sorajja et al. (24) examined 177 ASA patients and 177 age- and sex-matched 
myectomy patients, with a mean follow-up period of 5.7 years. They found annual SCD rates 
(including unknown death) of 1.3%/year after ASA and 1.1%/year after myectomy. The 
results of this study are in line with these findings, but the SCD risk after ASA is still higher 
than after myectomy (0.8%/year; HR for SCD after ASA vs. myectomy: 2.1; p = 0.04). 
 
 
Patient selection and specialised care 
The present findings may have implications for the clinical management of patients with 
obstructive HCM who are considered for septal reduction therapy. Patients who underwent 
myectomy had a statistically significantly lower risk for SCD compared with patients who 
underwent ASA. 
This, combined with a lower need for additional septal reduction therapy and lower 
periprocedural arrhythmic events, favors surgical myectomy over ASA when an invasive 
strategy is chosen, for example, in younger and otherwise healthy patients. In older patients or 
patients with comorbidities and drug-refractory symptoms, and appropriate septal anatomy, 
the expected survival after ASA is excellent, and in these patients, ASA is a valuable therapy. 
Open-heart surgery can be avoided, and rehabilitation is much faster. We recommend that a 
multi- disciplinary heart team (consisting of at least a cardiothoracic surgeon, an 
interventional cardiolo- gist, and a cardiologist specializing in the care of pa- tients with 
HCM) determines the optimal strategy for septal reduction. Also, in line with the 2003 
European Society of Cardiology and American College of Car- diology (25) and 2011 
American College of Cardiology Foundation and American Heart Association (26) 
guidelines, the procedure should be performed by experienced operators and confined to 




This study had several limitations. The 3 centers are all tertiary referral centers for the 
diagnostic and therapeutic care of patients with HCM, and the patient population might not 
represent the general HCM population. This referral and selec- tion bias could have 
influenced the results. Data collection was limited to variables that were routinely collected. 
Because rhythm documentation of the event was not available for all SCD cases, it was not 
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possible to ascertain that all deaths were arrhythmic in nature. Neither was it possible to 
correct for individual or local alterations of surgical or percutaneous technique, but all 
procedures were performed by experienced interventional cardiologists or cardio- thoracic 




Patients with obstructive HCM who are treated at referral centers for HCM care have good 
survival and low SCD risk, similar to that of patients with nonobstructive HCM. The SCD 
risk in patients after myectomy was lower than that after ASA and in the medical group. 
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